Nomenclature
Short Name:
BMX
Full Name:
Cytoplasmic tyrosine-protein kinase BMX
Alias:
- BMX NON-receptor tyrosine kinase
- Bone marrow kinase BMX
- Kinase Etk
- NTK38
- Protein tyrosine kinase BMX
- PSCTK3
- Cytoplasmic BMX
- EC 2.7.10.2
- Epithelial and endothelial tyrosine kinase
- ETK
Classification
Type:
Protein-tyrosine kinase
Group:
TK
Family:
Tec
SubFamily:
NA
Specific Links
Structure
Mol. Mass (Da):
78,011
# Amino Acids:
675
# mRNA Isoforms:
1
mRNA Isoforms:
78,011 Da (675 AA; P51813)
4D Structure:
Interacts with RUFY1 and RUFY2.
1D Structure:
3D Image (rendered using PV Viewer):
PDB ID
Subfamily Alignment
Domain Distribution:
Kinexus Products
Click on entries below for direct links to relevant products from Kinexus for this protein kinase.
hiddentext
Post-translation Modifications
For detailed information on phosphorylation of this kinase go to PhosphoNET
Acetylated:
K172, K181, K337, K343, K347, K395.
Serine phosphorylated:
S186, S226, S260, S261, S324, S425, S568.
Tyrosine phosphorylated:
Y40+, Y216, Y330, Y365, Y440, Y566+.
Ubiquitinated:
K413.
Distribution
Based on gene microarray analysis from the NCBI
Human Tissue Distribution
% Max Expression:
Mean Expression:
Number of Samples:
Standard Deviation:
% Max Expression:
Mean Expression:
Number of Samples:
Standard Deviation:
37
816
16
1053
0.6
13
9
14
4
98
19
206
24
526
62
1578
12
272
14
281
0.5
12
37
12
12
260
19
484
25
548
38
1345
9
210
10
205
2
42
44
59
1.2
26
32
57
22
484
102
587
3
57
30
78
0.5
12
8
5
3
71
28
156
0.4
9
7
8
1.1
24
114
48
2
55
24
116
1.2
26
61
54
13
297
56
346
3
66
27
147
2
37
30
70
2
44
28
59
2
36
25
82
3
58
27
158
39
877
45
2015
0.8
17
33
27
2
54
26
90
3
57
26
76
1.5
33
14
39
22
489
30
244
100
2235
21
4186
6
129
55
359
24
541
31
564
2
47
31
74
Evolution
Species Conservation
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
100
100
100
49.8
68
93
96.8
97.8
97.5
-
-
93
-
-
-
68.3
71.4
92
-
-
-
87.8
92.4
91
28.4
45.3
90
-
-
-
65.6
73.6
-
49.2
68.3
68
28.1
46.8
-
46.4
65.8
-
-
-
-
35.5
52.2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
For a wider analysis go to PhosphoNET Evolution in PhosphoNET
Binding Proteins
Examples of known interacting proteins
hiddentext
| No. | Name – UniProt ID |
|---|---|
| 1 | PAK1 - Q13153 |
| 2 | CASP3 - P42574 |
| 3 | STAT3 - P40763 |
| 4 | GAB1 - Q13480 |
| 5 | TP53 - P04637 |
| 6 | BTK - Q06187 |
| 7 | ITK - Q08881 |
| 8 | CRK - P46108 |
| 9 | ERBB2 - P04626 |
| 10 | EGFR - P00533 |
| 11 | BLNK - Q8WV28 |
Regulation
Activation:
Phosphorylation of Tyr-40 increases phosphotransferase activity and induced interaction with FAK. Phosphorylation of Tyr-566 induces interaction with PIK3R1 and STAT3. It is likely that activation also occurs through binding of phosphoinositides to the PH domain.
Inhibition:
NA
Synthesis:
NA
Degradation:
NA
Known Upstream Kinases
For further details on these substrates click on the Substrate Short Name or UniProt ID. Phosphosite Location is hyperlinked to PhosphoNET
predictions.
Based on in vitro and/or in vivo phosphorylation data
| Kinase Short Name | UniProt ID (Human) | Phosphosite Location | Phosphosite Sequence | Effect of Phosphorylation |
|---|
Known Downstream Substrates
For further details on these substrates click on the Substrate Short Name or UniProt ID. Phosphosite Location is hyperlinked to PhosphoNET
predictions.
Based on in vitro and/or in vivo phosphorylation data
| Substrate Short Name | UniProt ID (Human) | Phosphosite Location | Phosphosite Sequence | Effect of Phosphorylation |
|---|
Protein Kinase Specificity
Matrix of observed frequency (%) of amino acids in aligned protein substrate phosphosites
Matrix Type:
Predicted from the application of the Kinexus Kinase Substrate Predictor Version 2.0 algorithm, which was trained with over 10,000 kinase-protein substrate pairs and 8,000 kinase-peptide substrate pairs.
Domain #:
1
Inhibitors
For further details on these inhibitors click on the Compound Name and enter it into DrugKiNET or click on the ID's
Based on in vitro and/or in vivo phosphorylation data
| Compound Name | KD, Ki or IC50 (nM) | PubChem ID | ChEMBL ID | PubMed ID |
|---|
Disease Linkage
General Disease Association:
Cancer
Specific Cancer Types:
Prostate cancer
Comments:
BMX has been demonstrated to prevent apoptosis of nasopharyngeal carcinomas.
Gene Expression in Cancers:
TranscriptoNET (www.transcriptonet.ca) analysis with mRNA expression data retrieved from the National Center for Biotechnology Information's Gene Expression Omnibus (GEO) database, which was normalized against 60 abundantly and commonly found proteins, indicated altered expression for this protein kinase as shown here as the percent change from normal tissue controls (%CFC) as supported with the Student T-test in the following types of human cancers: Bladder carcinomas (%CFC= -45, p<0.0002); Brain oligodendrogliomas (%CFC= +62, p<0.102); Skin melanomas - malignant (%CFC= -72, p<0.001); and Vulvar intraepithelial neoplasia (%CFC= -56, p<0.025). The COSMIC website notes an up-regulated expression score for BMX in diverse human cancers of 453, which is close to the average score of 462 for the human protein kinases. The down-regulated expression score of 144 for this protein kinase in human cancers was 2.4-fold of the average score of 60 for the human protein kinases.
Mutagenesis Experiments:
Insertional mutagenesis studies in mice have not yet revealed a role for this protein kinase in mouse cancer oncogenesis.
Mutation Rate in All Cancers:
Percent mutation rates per 100 amino acids length in human cancers: 0.08 % in 25033 diverse cancer specimens. This rate is very similar (+ 3% higher) to the average rate of 0.075 % calculated for human protein kinases in general.
Mutation Rate in Specific Cancers:
Highest percent mutation rates per 100 amino acids length in human cancers: 0.37 % in 602 endometrium cancers tested; 0.35 % in 805 skin cancers tested; 0.35 % in 1093 large intestine cancers tested; 0.14 % in 1807 lung cancers tested.
Frequency of Mutated Sites:
None > 7 in 20,285 cancer specimens; 6 were S212S silent mutations
Comments:
Only 1 insertion, and no deletions or complex mutations are noted on the COSMIC website.